tert-butyl N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-(2,3,4,5,6-pentadeuteriophenyl)butan-2-yl]carbamate | 870073-16-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-(2,3,4,5,6-pentadeuteriophenyl)butan-2-yl]carbamate
• CAS: 870073-16-8
• 化学式: C₂₉H₄₇N₃O₄
• 分子量: 506.67
• InChiKey: LYMBPRXTWAXSBF-APDHQHSSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  90.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-(2,3,4,5,6-pentadeuteriophenyl)butan-2-yl]carbamate 在 N-乙基吗啉 、 甲烷磺酸 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 醋酸异丙酯 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  同位素标记为？HEA/HEE？合成标记的 HIV 蛋白酶抑制剂的部分？第二部分

  摘要：

  [H-2(5)]-Amprenavir and [H-2(5)]-saquinavir have been prepared from a common labeled precursor (1S, 2S)-(1-oxiranyl-2-[H-2(5)]phenylethyl)-carbamic acid tert-butyl ester, 1. Both of these compounds are in the 'HEA' class of HIV protease inhibitors. [H-2(5)]-Indinavir, a representative of the 'HEE' group of protease inhibitors, has also been synthesized. In the case of indinavir, IS-(2,2-dimethyl-8, 8a-dihydro-3aH-indeno-[1,2-d]-oxazol-3R-yl)-2-oxiranylmethyl-3-[H-2(5)]phenylpropan-1-one, 11, provided the [phenyl-H-2(5)]-HEE core structure for synthesis of the desired labeled compound. Copyright (c) 2005 John Wiley [ Sons, Ltd.

  DOI：

  10.1002/jlcr.913
• 作为产物：
  描述：

  N-叔丁基-十氢异喹啉-3(S)-甲酰胺 、 (2S,3S)-3-叔丁氧羰基-氨基-1,2-环氧-4-苯基-D5-丁烷 以 异丙醇 为溶剂， 反应 4.0h， 以78%的产率得到tert-butyl N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-(2,3,4,5,6-pentadeuteriophenyl)butan-2-yl]carbamate
  参考文献：
  名称：

  同位素标记为？HEA/HEE？合成标记的 HIV 蛋白酶抑制剂的部分？第二部分

  摘要：

  [H-2(5)]-Amprenavir and [H-2(5)]-saquinavir have been prepared from a common labeled precursor (1S, 2S)-(1-oxiranyl-2-[H-2(5)]phenylethyl)-carbamic acid tert-butyl ester, 1. Both of these compounds are in the 'HEA' class of HIV protease inhibitors. [H-2(5)]-Indinavir, a representative of the 'HEE' group of protease inhibitors, has also been synthesized. In the case of indinavir, IS-(2,2-dimethyl-8, 8a-dihydro-3aH-indeno-[1,2-d]-oxazol-3R-yl)-2-oxiranylmethyl-3-[H-2(5)]phenylpropan-1-one, 11, provided the [phenyl-H-2(5)]-HEE core structure for synthesis of the desired labeled compound. Copyright (c) 2005 John Wiley [ Sons, Ltd.

  DOI：

  10.1002/jlcr.913

文献信息

• Isotope labeled ?HEA/HEE? moiety in the synthesis of labeled HIV-protease inhibitors?Part II
  作者：I. Victor Ekhato、Yuan Liao、Mihaela Plesescu

  DOI：10.1002/jlcr.913

  日期：2005.3.15

  [H-2(5)]-Amprenavir and [H-2(5)]-saquinavir have been prepared from a common labeled precursor (1S, 2S)-(1-oxiranyl-2-[H-2(5)]phenylethyl)-carbamic acid tert-butyl ester, 1. Both of these compounds are in the 'HEA' class of HIV protease inhibitors. [H-2(5)]-Indinavir, a representative of the 'HEE' group of protease inhibitors, has also been synthesized. In the case of indinavir, IS-(2,2-dimethyl-8, 8a-dihydro-3aH-indeno-[1,2-d]-oxazol-3R-yl)-2-oxiranylmethyl-3-[H-2(5)]phenylpropan-1-one, 11, provided the [phenyl-H-2(5)]-HEE core structure for synthesis of the desired labeled compound. Copyright (c) 2005 John Wiley [ Sons, Ltd.